Prescribers give thumbs up to Biotie/Lundbeck's Selincro
This article was originally published in Scrip
Selincro (nalmefene), the alcohol-dependence drug licensed to Lundbeck from Finnish firm Biotie, is going down well with prescribers, says Andreas Eggert, Lundbeck's senior vice-president of global product strategy & portfolio development. as the company prepares for its imminent launch in in the first markets where it has won reimbursement: the Netherlands and Denmark .
You may also be interested in...
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.